Login to Your Account

Colorectal Cancer the Next Bet?

Failed Phase III Dims Picoplatin's SCLC Chances, Partnering Plans

By Jennifer Boggs

Tuesday, November 17, 2009
Shares of Poniard Pharmaceuticals Inc. tumbled 76 percent on disappointing data from its Phase III trial of picoplatin in small-cell lung cancer, news that's certain to hamper ongoing discussions for a much-needed partnership. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription